EDUCATION

M.D., 1979, Indiana University School of Medicine, Indianapolis, Indiana.
B.S., 1975, Indiana Wesleyan University, Marion, Indiana.


INTERNSHIP AND RESIDENCY

Dermatology Residency, 1984,
University of Texas Health Science Center, San Antonio, Texas.

Internal Medicine Residency, 1982,
University of Texas Health Science Center, San Antonio, Texas.

Internal Medicine Internship, 1980,
University of Texas Health Science Center, San Antonio, Texas.

CERTIFICATION

Diplomat of the American Board of Dermatology, 1985.
Diplomat of the American Board of Internal Medicine, 1982.


LICENSURE

Oklahoma Medical License,1985.
Texas Medical License, 1980.
Indiana Medical License, 1979.


HONORS AND MEMBERSHIPS

Fellow, American College of Physicians.
Fellow, American Academy of Dermatology.
Member, Alpha Omega Alpha (A.O.A.), Medical Honor Society.
Member, American Medical Association.
Member, Oklahoma State Medical Association.
Member, Oklahoma State Dermatological Society.
Member, Tulsa County Medical Society.
Member, Tulsa Dermatological Society.
Outstanding Achievement Award in Science and Health, 1993, Indiana Wesleyan University.


APPOINTMENTS AND POSITIONS

Board of Directors, Tulsa County Medical Society, 2003 - 2005
Chairman, Board of Censors, Tulsa County Medical Society, 2002.
Member, Board of Censors, Tulsa County Medical Society, 2000 – 2002.
Active Staff, Hillcrest Medical Center, Tulsa, Oklahoma 1993 – Present.
Active Staff, Saint Francis Hospital, Tulsa, Oklahoma 1993 – Present.
Active Staff, Hillcrest Specialty Hospital, Tulsa, Oklahoma 9/99 – Present.
Active Staff, Saint John Medical Center, Tulsa, Oklahoma 1988 – Present.
Clinical Associate Professor, Dermatology, Univ. of OK College of Medicine, Tulsa, Oklahoma 1988 – Present.
Adjunct Faculty Member, Oklahoma State Univ, College of Osteopathic Medicine, Tulsa, OK 2007 - Present.
President, Oklahoma State Dermatological Society, 1986 – 1987.
Secretary/Treasurer, Oklahoma State Dermatological Society, 1986 – 1987.
Assistant Professor, Dermatology, Oral Roberts University School of Medicine, Tulsa, Oklahoma 1985 – 1988.
Assistant Instructor, Dermatology, University of TX Health Science Center, San Antonio, Texas 1983 – 1984.



PROFESSIONAL EXPERIENCE

1988 – Present
Formed and developed SMITH DERMATOLOGY (dba), Steven A. Smith, M.D., Dermatology, P.C., a full-time dermatology practice and professional corporation.

1985 – 1988
Formed the Section of Dermatology, Department of Internal Medicine, Oral Roberts University School of Medicine.

Developed and taught the dermatology curriculum for third-year medical students.

Clinical director of dermatology instruction for fourth-year medical student electives – Internal medicine, family practice, and pediatric residency instruction.


PROFESSIONAL ACCOMPLISHMENTS

1990 – Present
President/Founder of LOMA LUX LABORATORIES (dba), Plymouth Pharmaceuticals, Inc.

Developed and marketed a new line of four oral OTC products and four prescription products for treatment of chronic skin conditions, including eczema, acne, psoriasis and nickel allergy.

2002
Invited to lecture at the American Osteopathic College of Dermatology Meeting, Hilton Head, South Carolina.

2000
Multiple lectures presented at Russian Dermatology Departments in Moscow, Russia, titled “Nickel and Psoriasis”.

1999
Poster presentation at the American Academy of Dermatology annual meeting,
New Orleans, Louisiana. Topic: “Low Nickel Patch Test Sensitivity in Psoriasis Vulgaris.”

1999
Lecture to General Session, American College for Advancement in Medicine Annual Meeting, Reno, Nevada, titled “Nickel and Psoriasis”.

1997
Lecture presentation at the H & H Dermatology Seminar, Santa Fe, New Mexico, titled “Nickel and Psoriasis”.

1996
Developed and sponsored a scientifically controlled study to determine the frequency of cutaneous nickel sensitivity in psoriatic patients versus controls. Statistically significant differences were documented.

1995
Developed, sponsored, and conducted a randomized, double-blind, placebo-controlled clinical study using a homeopathic formulation of mineral compounds for seborrheic dermatitis. Statistically significant positive study results led to further product development.

1994
Developed, sponsored, and carried out, with FDA approval, a second placebo-controlled, double-blind, clinical study using a novel mineral compound treatment for psoriasis vulgaris (sixty subjects). Statistically significant positive study results led to further product development.

1993
Sponsored an F.D.A. Investigational New Drug application (I.N.D. #40,034) for nickel dibromide oral treatment of psoriasis vulgaris. Clinical protocol for a double-blind, placebo-controlled, randomized, dose range finding study developed.

Poster presentations at the Oklahoma American College of Physicians annual meeting, Shangri-La, Oklahoma. Topics: “Double-Blind Placebo-Controlled Study of Nickel Dibromide in Twenty-One Psoriatic Patients” and “Analysis of Serum Nickel Concentration in Psoriatic Patients and Healthy Controls”.

Oklahoma State Dermatological Society Annual Meeting speaker and Research Day Annual Meeting speaker, The University of Oklahoma Health Science Center, College of Medicine, Tulsa, Oklahoma. Topics: “Double-Blind Placebo-Controlled Study of Nickel Dibromide in Twenty-One Psoriatic Patients” and “Analysis of Serum Nickel Concentration in Psoriatic Patients and Healthy Controls”.

1991 – 1992
Developed, sponsored and carried out, with local IRB approval, the first placebo-controlled, double-blind, clinical study using a novel mineral compound treatment for psoriasis vulgaris (twenty-five subjects). Statistically significant positive study results led to further product development and publication (see below).

1990 – 1991
Developed and sponsored an international open study of five psoriasis vulgaris subjects using a novel mineral compound therapy. Positive study results documenting safety and efficacy led to further study.

1990
Developed, sponsored, and carried out a pilot study on one psoriasis vulgaris subject employing a novel mineral compound therapy. Positive study results documenting safety and efficacy led to further study.

Developed, sponsored and carried out a clinical study comparing baseline serum nickel levels in psoriasis vulgaris subjects compared with healthy volunteers. Statistically significant differences were documented leading to publication (see below).

1989
Organized and presided over the annual Meeting of the Oklahoma State Dermatological Society.

1987
Organized fund raising for the annual Meeting of the Oklahoma State Dermatological Society.

1984
Assistant Clinical Investigator in a pharmaceutical company sponsored, multi-center drug trial treating pre-cancerous skin lesions (actinic keratoses) with an investigational, topical, chemotherapeutic agent. Specific assignments included clinical diagnosis, skin biopsy documentation, and record keeping functions.

1983 – 1984
Conference Speaker, Combined Texas/Mexico Dermatology Societies – Meeting, Cuarnaraca, Mexico.
Topic: Localized Lepromatous Leprosy.
South Central Dermatological Society – Meeting, San Antonio, Texas.
Topic: Localized Lepromatous Leprosy.

1982 – 1983
Assistant Clinical Investigator in a pharmaceutical company sponsored, multi-center drug trial treating fungal infections (tinea pedis) with an investigational, topical, anti-fungal cream. Specific assignment consisted of assisting culture and identification of fungal skin samples.


ABSTRACTS AND PUBLICATIONS

2002
Smith, S.A., Baker, A.E., Williams, J.H. Jr., “Effective Treatment of Seborrheic Dermatitis Using a Low Dose, Oral Homeopathic Medication Consisting of Potassium Bromide, Sodium Bromide, Nickel Sulfate, and Sodium Chloride in Double-Blind, Placebo-Controlled Study” Alternative Medicine Review; 7(1):59-67.

1997
Smith, S.A., Young, T.R., Winsjansen, E., Baker, A.E., and Williams, J.H. Jr. “Improvement of Psoriasis Vulgaris With Oral Nickel Dibromide”, Arch.Derm., 133 (5):661-663.

1994
Smith, S.A., Aamir, F., Otis, M.P.B. “Elevated Serum Nickel Concentration In Psoriasis Vulgaris”, Internat.J.Derm., 11 (11):783-785.

1993
Smith, S.A., Otis, M.P.B., “Analysis of Serum Nickel Concentration in Psoriatic Patients and Healthy Controls”, University of Oklahoma College of Medicine Research Day, Tulsa, Oklahoma.

1993
Smith, S.A., Young, T.R., Barranco, V.P., “Double-Blind Placebo-Controlled Crossover Study of Nickel Dibromide in Twenty-One Psoriatic Patients”, University of Oklahoma College of Medicine Research Day, Tulsa, Oklahoma.

1993
Smith, S.A., “Pressure Necrosis”, J. Assoc. Military Derm., 9:78-83(1993).

1986
Smith, S.A., Day, C. L., and Vanderploeg, D.E., “Eruptive Widespread Spitz Nevi”, J. Amer. Acad. Derm., 15:1155-1159.

PATENTS

U.S. Patents
Patent number 5716646
Method and compositions for treating arthritis

Patent number 5171581
Method and compositions for treating
psoriasis

Patent number 5433954
Method and compositions for treating psoriasis
seborrheic dermatitis and eczema

Patent number 6613800
Method and compositions for treating psoriasis,
eczema, seborrhea and arthritis

Patent application 11,277,083
Method and composition for treating acne

Israel Patent
Patent number 97855
Method and composition for treating psoriasis

Canadian Patent
Patent number 2,081,911
Method and composition for treating psoriasis

Mexican Patent
Patent number 174,710
Method and apparatus for treating psoriasis

Return to Top of Page

Back to Physicians page.